Angiotensin-converting enzyme-2 and interleukin-12 serum level as indicator to severity between COVID-19 patients

The Coronavirus, one of the most rapidly spreading respiratory viruses, caused a worldwide epidemic that killed about six million people. This led to the fast development of several vaccines and drugs to reduce disease severity and speed patient recovery. This study aimed to identify the serum level...

Full description

Saved in:
Bibliographic Details
Published in:Journal of applied and natural science 2022-06, Vol.14 (2), p.433-436
Main Authors: Hasan, Huda Khadim, Al-Khafaji, Noor Salman Khadim
Format: Article
Language:English
Subjects:
ACE2
Alveoli
Angiotensin
Angiotensin-converting enzyme 2
Conversion
Coronaviruses
COVID-19
Cytokines
Disease transmission
Diuretics
Drug development
Enzymes
Epidemics
Immunosuppressive agents
Interleukin 12
Interleukins
Peptidyl-dipeptidase A
Serum levels
Vaccines
Viral diseases
Viruses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Coronavirus, one of the most rapidly spreading respiratory viruses, caused a worldwide epidemic that killed about six million people. This led to the fast development of several vaccines and drugs to reduce disease severity and speed patient recovery. This study aimed to identify the serum levels of each of the angiotensin-converting enzyme-2 and interleukin-12  .The severity of infection in coronavirus COVID-19 patients was compared to immune levels of these cytokines and receptors in the different cases of COVID-19 patients. This case-control study included 90 blood samples from COVID-19 patients with ages between 15-80 years. Results revealed that the serum levels of both angiotensin-converting enzyme-2 ( ACE-2) and interleukin-12 (IL-12) were measured in COVID-19 patients and the results were compared using an independent T-test, it was found that their levels for interleukin-12 revealed a significant difference (P ≤0.05) in the serum levels of severe cases when compared with non-severe cases. There was an increase in the serum level of IL-12 in severe cases was 33.340 ng/L, in the serum level and in non-severe cases was 20.913 ng/L. ( P ≤0.000), and for angiotensin-converting enzyme-2 this study revealed a significant difference in ACE-2 serum levels in severe cases (P ≤0.05) when compared with the non-severe cases of patients with COVID 19.  The serum level of ACE-2 in severe cases was 11.023 ng/ml, and in non-severe cases, it was 5.443ng/ml ( P ≤0.000). It was concluded that the emerging coronavirus works to create an immune storm represented by raising the serum levels of both ACE-2 and IL-12 that contribute to the damage to the alveoli in severely COV-19 patients.            
ISSN:0974-9411
2231-5209
DOI:10.31018/jans.v14i2.3410